Since its establishment in 1992, BioKangtai has undertaken a number of national, provincial and municipal key scientific research projects and technology development tasks, and has possessed core technologies such as polyvalent vaccines, genetic engineering vaccines and other new technology R&D and industrialization core competitiveness. The company has 8 research and development carriers such as academician expert workstations, and its products cover more than 3,130 provinces, municipalities and autonomous regions. Among them, the self-developed cell-free whitebait b-type Haemophilus influenzae combined vaccine is the domestically-innovated “quadruple vaccine”, and the 60-microg hepatitis B vaccine specifically targeting unresponsive people has the “National Key New Product” title.

30+Years

Development History

90000

Production base

30+Item

In vaccine research

400+

Research staff

8+

Available vaccine varieties

Company news Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.
2022-08-31

Licensing and Agency Agreement Signed between Beijing Minhai (Biokangtai) and Phil. Pharmawealth, Inc.

More
Industry news China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines
2021-02-09

China, Malaysia companies inks deal on clinical trial, commercialization of COVID-19 vaccines

More
News